>아시아 태평양 탁산 시장, 유형별(파클리탁셀, 도세탁셀, 카바지탁셀), 약물 유형(제네릭, 브랜드), 제형(리포좀, 나노입자, 고분자 미셀, 기타), 연령대(성인, 노인), 응용 분야(유방암, 비소세포 폐암, 췌장암, 난소암, 전립선암, 기타), 최종 사용자(병원, 외래 수술 센터 , 전문 클리닉, 기타) 유통 채널(소매 판매, 직접 입찰) 산업 동향 및 2029년까지의 전망.
시장 분석 및 통찰력
아시아 태평양 탁산 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 8.7%의 CAGR로 성장하고 있다고 분석합니다. 탁산 약물 치료의 기술적 발전과 컴퓨터 지원 진단의 증가하는 응용 프로그램이 결합되어 예측 기간 동안 탁산 시장 성장을 견인하는 또 다른 요인입니다.
그러나 약물과 관련된 높은 비용과 혈전, 백혈구 감소증, 알레르기, 설사, 체중 감소와 같은 부작용은 시장 성장을 제한할 것입니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 탁산 시장 성장의 기회로 작용합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 |
|
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
|
다루는 세그먼트 |
유형별(파클리탁셀, 도세탁셀 및 카바지탁셀), 약물 유형(브랜드 및 제네릭), 제형(탁산을 함유한 리포좀 및 폴리머 미셀, 탁산의 하이드로겔 제형, 나노입자 제형 및 기타), 연령대별(성인 및 노인), 적용 분야(난소암, 유방암, 전립선암, 비소세포 폐암 및 기타), 최종 사용자(병원, 외래 수술 센터, 전문 병원 및 기타), 유통 채널(직접 입찰, 소매 판매) |
|
적용 국가 |
중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 베트남, 말레이시아, 인도네시아, 필리핀 및 기타 아시아 태평양 지역 |
|
시장 참여자 포함 |
Viatris Inc., Sandoz International GmbH(Novartis 사업부), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG(Fresenius SE & Co. KGaA의 자회사), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC 등이 있습니다. |
탁산 시장 정의
The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as mitosis inhibitors and are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Furthermore, increasing use of taxane drugs due to rising prevalence of chronic diseases, surging prevalence of cancer, and increasing investment for healthcare infrastructure. These factors increase in the demand for taxane market has encouraged the key market players to implement newer technologies and strategies through product launches, acquisition, strategies and agreements.
Taxane Market Dynamics
Drivers
- The rise in incidence of cancer
Cancer has a major impact on society in the United States and worldwide. Cancer statistics describe what happens in large groups of people and provide a picture in time of the burden of cancer on society. Taxol, an antimitotic agent, used to treat cancer, blocks cancer cell growth by stopping cell division, resulting in cell death.
According to National Cancer Institute (NCI), a funded clinical trial found that 30 percent of patients with advanced ovarian cancer responded positively to taxane treatment. In clinical practice, the taxane is now standard therapy in metastatic breast cancer. Today, taxol is on the World Health Organization's Model List of Essential Medicines, a cytotoxic drug that kills cancer cells. It treats breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and AIDS-related Kaposi sarcoma.
- The funding by the government and investment in research and development
Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to the implementation of taxane by specialty treatment programs have been observed. Certain attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries. The issues around sustainability, productivity, and patient impact of drug development have never been and will not simply be a product of industry.
The funding by the government would result in the patient's safety, cost-savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.
Restraint
-
Side effects of drugs incurred with the taxane drugs
Taxanes belong to a class of diterpenes. Taxane drugs (paclitaxel and docetaxel) are used as chemotherapeutic agents. Due to ongoing clinical trials, research studies, type of cancer, type of treatment plan, and drug dosage, the present high cost is expected to show a descending trend in the future. Taxane drugs are most effective for treating breast and prostate cancer. However, certain side effects have been reported. The adverse complications or side effects reported would lead to a decline in sales of the taxane drugs, which would limit the sales of the drugs. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.
Opportunity
-
Strategic initiative by market players
The demand for taxane market has increased in the U.S. and Europe owing to the timely treatment of alcohol and opioid disorders. These favorable factors enhance the need for taxane, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity to help in future growth and drive market growth.
Challenge
- The lack of skilled professionals required for taxane drug treatment
The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.
Physician supply is a term used to describe the number of trained physicians working in a healthcare system or labor market. It is dependent on the number of graduates and the retention rates of the profession. The physician shortage is a growing concern in many countries around the world.
The World Health Organization (WHO) estimated a global shortage of 4.3 million physicians, nurses, and other health professionals. Despite the strong evidence for the effectiveness of drugs in reducing morbidity and mortality, increasing treatment retention, and improving well-being for individuals with taxane, numerous barriers prevent broader access to taxane drug-based treatment.
Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers, with only a small minority rating themselves as competently providing supportive care. There is an urgent need for the education of professionals for the treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. Therefore, it is apparent that the availability of professionals with adequate skills is challenging the market growth.
Post COVID-19 Impact on Taxane Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the taxane market.
Recent Developments
- In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS (insulin glargine), allowing for substitution at the pharmacy counter. Viatris is committed to improving patient access to sustainable, quality and more affordable healthcare. This has helped the company to grow their product portfolio.
- In May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This prescription oral medicine is immediately available to patients via specialty pharmacies, with a $0 co-pay program for eligible patients. Sandoz is putting patients first by expanding access to generic pirfenidone for those with this rare disease, who will benefit from a more affordable, yet equally effective treatment. This has helped the company to grow its market position and business.
Taxane Scope and Market Size
탁산 시장은 유형, 약물 유형, 제형, 연령대, 응용 분야, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
유형별로
- 파클리탁셀
- 도세탁셀
- 카바지탁셀
아시아 태평양 탁산 시장은 유형을 기준으로 파클리탁셀, 도세탁셀, 카바지탁셀로 구분됩니다.
응용 프로그램으로
- 난소암
- 유방암
- 전립선암
- 비소세포 폐암
- 다른
아시아 태평양 탁산 시장은 응용 분야별로 난소암, 유방암, 전립선암, 비소세포 폐암 등으로 구분됩니다.
약물 유형별
- 제네릭
- 브랜드화
약물 유형을 기준으로 아시아 태평양 탁산 약물 시장은 브랜드 약물과 제네릭 약물로 구분됩니다.
제형에 따라
- 리포좀
- 나노입자
- 고분자 미셀
- 기타
아시아 태평양 지역의 탁산 시장은 제형을 기준으로 리포좀, 나노입자, 고분자 미셀 등으로 구분됩니다.
연령대별
- 성인
- 노인
연령대를 기준으로 볼 때 아시아 태평양 지역의 탁산 시장은 성인과 노인으로 구분됩니다.
최종 사용자별
- 병원
- 외래 수술 센터
- 전문 병원
- 기타
아시아 태평양 지역의 탁산 시장은 최종 사용자를 기준으로 병원, 외래 수술 센터, 전문 병원 및 기타로 구분됩니다.
유통 채널별
- 직접 입찰
- 소매 판매
아시아 태평양 탁산 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매로 구분됩니다.
아시아 태평양 탁산 시장 지역 분석
탁산 시장을 분석하고, 유형, 약물 유형, 제형, 연령대, 응용 분야, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
탁산 시장 보고서에서 다루는 국가는 중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 베트남, 말레이시아, 인도네시아, 필리핀 및 기타 아시아 태평양 지역입니다.
2022년에는 GDP가 높은 가장 큰 소비자 시장을 따라 주요 시장 참여자가 존재하기 때문에 중국이 우세합니다. 중국은 약물 치료의 기술 발전으로 인해 성장할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
탁산 시장은 또한 모든 국가의 의료 산업 성장에 대한 자세한 시장 분석을 제공합니다. 게다가, 의료 서비스와 치료, 규제 시나리오의 영향, 탁산 시장에 대한 추세 매개변수에 대한 자세한 정보를 제공합니다.
경쟁 환경 및 탁산 시장 점유율 분석
Taxane 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 Taxane 약물과 관련된 회사의 초점에만 관련이 있습니다.
Taxane 시장에서 거래하는 주요 기업으로는 Viatris Inc., Sandoz International GmbH(Novartis Division), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG(Fresenius SE & Co. KGaA의 자회사), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC 등이 있습니다.
합병, 인수 및 주요 시장 참여자 간의 합의와 같은 전략적 제휴는 탁산 약물의 성장을 더욱 가속화할 것으로 예상됩니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 Taxane 시장에서 회사의 입지를 강화하고 조직의 수익 성장에도 도움이 됩니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 ASIA PACIFIC TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 ASIA PACIFIC TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 ASIA PACIFIC TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 ASIA PACIFIC TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 ASIA PACIFIC TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 ASIA PACIFIC TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 ASIA PACIFIC TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 ASIA PACIFIC TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 ASIA PACIFIC TAXANE MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 INDIA
16.1.4 SOUTH KOREA
16.1.5 AUSTRALIA
16.1.6 INDONESIA
16.1.7 THAILAND
16.1.8 PHILIPPINES
16.1.9 VIETNAM
16.1.10 SINGAPORE
16.1.11 MALAYSIA
16.1.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 ASIA PACIFIC TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 CHINA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 CHINA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 CHINA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 CHINA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 CHINA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 CHINA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 CHINA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 CHINA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 CHINA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 CHINA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 CHINA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 CHINA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 CHINA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 JAPAN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 JAPAN PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 JAPAN TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 JAPAN TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 JAPAN TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 JAPAN PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 JAPAN DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 JAPAN CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 JAPAN TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 JAPAN ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 JAPAN GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 JAPAN TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 JAPAN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 JAPAN RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 INDIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 INDIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 INDIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 INDIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 INDIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 INDIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 INDIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 INDIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 INDIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 INDIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 INDIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 INDIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 INDIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 INDIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 SOUTH KOREA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 SOUTH KOREA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 SOUTH KOREA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 SOUTH KOREA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 99 SOUTH KOREA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 SOUTH KOREA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 101 SOUTH KOREA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 102 SOUTH KOREA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 103 SOUTH KOREA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 104 SOUTH KOREA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 105 SOUTH KOREA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 106 SOUTH KOREA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 SOUTH KOREA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 SOUTH KOREA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 112 AUSTRALIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 113 AUSTRALIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 AUSTRALIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 115 AUSTRALIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 116 AUSTRALIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 117 AUSTRALIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 118 AUSTRALIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 119 AUSTRALIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 AUSTRALIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 INDONESIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 INDONESIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 INDONESIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 INDONESIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 INDONESIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 INDONESIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 129 INDONESIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 130 INDONESIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 131 INDONESIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 132 INDONESIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 133 INDONESIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 134 INDONESIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 INDONESIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 INDONESIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 THAILAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 THAILAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 THAILAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 140 THAILAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 141 THAILAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 THAILAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 143 THAILAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 144 THAILAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 145 THAILAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 146 THAILAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 147 THAILAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 148 THAILAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 149 THAILAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 THAILAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 151 PHILIPPINES TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 PHILIPPINES PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 PHILIPPINES TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 155 PHILIPPINES TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 156 PHILIPPINES PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 157 PHILIPPINES DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 158 PHILIPPINES CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 159 PHILIPPINES TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 160 PHILIPPINES ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 PHILIPPINES TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 VIETNAM TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 VIETNAM PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 VIETNAM TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 168 VIETNAM TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 169 VIETNAM TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 170 VIETNAM PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 171 VIETNAM DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 172 VIETNAM CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 173 VIETNAM TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 174 VIETNAM ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 175 VIETNAM GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 176 VIETNAM TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 VIETNAM TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 VIETNAM RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 SINGAPORE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SINGAPORE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 SINGAPORE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 182 SINGAPORE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 183 SINGAPORE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 184 SINGAPORE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 185 SINGAPORE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 186 SINGAPORE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 187 SINGAPORE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 188 SINGAPORE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 189 SINGAPORE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 190 SINGAPORE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 191 SINGAPORE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 192 SINGAPORE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 193 MALAYSIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 MALAYSIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 MALAYSIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 196 MALAYSIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 197 MALAYSIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 198 MALAYSIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 199 MALAYSIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 200 MALAYSIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 201 MALAYSIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 202 MALAYSIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 203 MALAYSIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 204 MALAYSIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 MALAYSIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 MALAYSIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 207 REST OF ASIA-PACIFIC TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 ASIA PACIFIC TAXANE MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC TAXANE MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA PACIFIC TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE ASIA PACIFIC TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 ASIA PACIFIC TAXANE MARKET: BY TYPE, 2021
FIGURE 17 ASIA PACIFIC TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 ASIA PACIFIC TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 ASIA PACIFIC TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 ASIA PACIFIC TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 ASIA PACIFIC TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 ASIA PACIFIC TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 ASIA PACIFIC TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 ASIA PACIFIC TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 ASIA PACIFIC TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 ASIA PACIFIC TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 ASIA PACIFIC TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 ASIA PACIFIC TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 ASIA PACIFIC TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 ASIA PACIFIC TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 ASIA PACIFIC TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 ASIA PACIFIC TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 ASIA PACIFIC TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 ASIA PACIFIC TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 ASIA PACIFIC TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 ASIA PACIFIC TAXANE MARKET: BY END USER, 2021
FIGURE 37 ASIA PACIFIC TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 ASIA PACIFIC TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 ASIA PACIFIC TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 ASIA PACIFIC TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 ASIA PACIFIC TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 ASIA PACIFIC TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 ASIA PACIFIC TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 ASIA-PACIFIC TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 ASIA-PACIFIC TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 ASIA-PACIFIC TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 ASIA-PACIFIC TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 ASIA PACIFIC TAXANE MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
